Global Biosimilars Market Value Could Hit $55B by 2020

The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth primarily driven by a promising pipeline in active development and government efforts to reduce healthcare spending, according to business intelligence provider GBI Research.

The company’s latest CBR Pharma report states that biologics currently account for between 17–20 percent of the pharmaceutical arena, with a value of nearly $200 billion, and these products may replace 70 percent of chemical drugs in the next two decades.

The 30 percent to 50 percent reduction in biosimilar prices compared with branded biologics could lead to considerable savings in healthcare expenditure.

There are currently 642 biosimilar trials being conducted, with 146 unique molecules. Biosimilars are most focused on oncology therapy, with a 36 percent share, while immunology treatment comprises 21 percent of the pipeline, meaning these two segments account for...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.dddmag.com/articles/2015/06/global-biosimilars-market-value-could-hit-55b-2020